PEGylated L-asparaginase
US11046946B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | May 18, 2020 |
| Grant date | Jun 29, 2021 |
| Priority date | — |
| Expiry date | May 18, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a conjugate of a protein having substantial L-asparagine amino hydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight of about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.